Control of relapse due to minimal residual disease (MRD) by cell-mediated cytokine-activated immunotherapy in conjunction with bone marrow transplantation
- 1 June 1991
- journal article
- review article
- Published by Elsevier in Bailliere's Clinical Haematology
- Vol. 4 (3) , 715-725
- https://doi.org/10.1016/s0950-3536(09)90009-9
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemiaCancer Immunology, Immunotherapy, 1990
- EFFECT OF METHOTREXATE ON RELAPSE AFTER BONE-MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKAEMIAThe Lancet, 1989
- ‘Nonspecific’ MHC-unrestricted killer cells and their receptorsImmunology Today, 1987
- Immune regulation of the L5178Y murine tumor-dormant state. I. In vivo and in vitro effects of prostaglandin E2 and indomethacin on tumor cell growth.The Journal of Experimental Medicine, 1986
- BONE MARROW TRANSPLANTATION WITH T-CELL-DEPLETED GRAFTSTransplantation, 1986
- ELIMINATION OF GRAFT-VERSUS-HOST DISEASE BY IN-VITRO DEPLETION OF ALLOREACTIVE LYMPHOCYTES WITH A MONOCLONAL RAT ANTI-HUMAN LYMPHOCYTE ANTIBODY (CAMPATH-1)The Lancet, 1984
- Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivityNature, 1979
- Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow GraftsNew England Journal of Medicine, 1979
- Spontaneous murine B-cell leukaemiaNature, 1978
- GRAFT VERSUS LEUKEMIATransplantation, 1973